logo
logo
HomeAbout UsPlatformInsights

Clinical Trial Insights

AllClinical TrialRegulatoryMerger & AcquisitionsBlogs
Beam one-ups Wave as both show promise of genetic editing for AATDClinical Trial Updates

21 May 2026

Beam one-ups Wave as both show promise of genetic editing for AATD

Beam Therapeutics and Wave Life Sciences recently presented encouraging Phase 1/2 and Phase 1b/2a data, respectively, for their genetic editing therapies...

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next DecadeClinical Trial Updates

21 May 2026

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Propanc Biopharma's CEO, James Nathanielsz, forecasts significant medical breakthroughs in pancreatic cancer treatment over the next decade, citing recent...

AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritisClinical Trial Updates

21 May 2026

AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis

UCB's Bimzelx demonstrated superior efficacy over AbbVie's Skyrizi in a Phase 3 head-to-head study for psoriatic arthritis. At 16 weeks, 49.1% of patients on...

BioMarin drug acquired in buyout misses goal in rare disease studyClinical Trial Updates

21 May 2026

BioMarin drug acquired in buyout misses goal in rare disease study

BioMarin Pharmaceutical's experimental rare disease drug, BMN 401, acquired through a $270 million purchase of Inozyme, failed to meet one of its two...

Novo Nordisk to Unveil Semaglutide Data for Liver Disease CrisisClinical Trial Updates

21 May 2026

Novo Nordisk to Unveil Semaglutide Data for Liver Disease Crisis

Novo Nordisk is presenting new data at the EASL Congress 2026, highlighting semaglutide's role in addressing Metabolic Dysfunction-associated Steatohepatitis...

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer PatientsClinical Trial Updates

21 May 2026

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

Propanc Biopharma, Inc. has engaged a European Contract and Development Manufacturing Organization (CDMO) for the GMP production of its lead asset, PRP. This...

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticityClinical Trial Updates

21 May 2026

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

Ipsen announced late-breaking results from its Phase IV DIRECTION trial, the first head-to-head, double-blind study comparing Dysport (abobotulinumtoxinA) to...

Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3Clinical Trial Updates

21 May 2026

Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3

Regeneron's investigational LAG-3 inhibitor fianlimab, in combination with its FDA-approved PD-1 blocker Libtayo, failed to demonstrate significant survival...

Revolution Medicines' RAS Inhibitor Doubles Survival in Phase 3 Pancreatic Cancer TrialClinical Trial Updates

21 May 2026

Revolution Medicines' RAS Inhibitor Doubles Survival in Phase 3 Pancreatic Cancer Trial

Revolution Medicines' RAS inhibitor, daraxonrasib, achieved a significant breakthrough in a Phase 3 trial for advanced pancreatic cancer, doubling patient...

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATDClinical Trial Updates

21 May 2026

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

Sanofi announced positive results from the global ElevAATe Phase 2 study, demonstrating the superiority of investigational efdoralprin alfa over...

Merck ADC, licensed from China, hits mark in first big global trialClinical Trial Updates

21 May 2026

Merck ADC, licensed from China, hits mark in first big global trial

Merck & Co. announced positive results from a global Phase 3 trial of sacituzumab tirumotecan (Sac-TMT), an antibody-drug conjugate licensed from...

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancerClinical Trial Updates

18 May 2026

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

Novartis announced new data from the PSMAddition study, demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto (lutetium (177Lu)...

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic MelanomaClinical Trial Updates

18 May 2026

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

Regeneron announced that its Phase 3 trial evaluating fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) for first-line unresectable...

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfactionClinical Trial Updates

18 May 2026

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Ipsen presented positive first-in-class Phase II data for corabotase in moderate-to-severe glabellar lines at the 2026 Scale Symposium. The investigational...

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE TrialClinical Trial Updates

18 May 2026

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

Moleculin Biotech, Inc. reported its first quarter 2026 financial results and provided a significant clinical update on its pivotal MIRACLE Phase 2B/3 trial....

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 ResultsClinical Trial Updates

18 May 2026

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

Propanc Biopharma announced corporate progress and Q3 financial results for the period ending March 31, 2026. The company is advancing its lead asset, PRP,...

Genmab Drops Two Antibody Assets, Including Another ProfoundBio ADCClinical Trial Updates

18 May 2026

Genmab Drops Two Antibody Assets, Including Another ProfoundBio ADC

Genmab has discontinued two clinical programs: GEN1286, an antibody-drug conjugate (ADC) from its 2024 ProfoundBio acquisition, due to an unfavorable...

REGENXBIO slumps after serious side effects mar Duchenne gene therapy resultsClinical Trial Updates

15 May 2026

REGENXBIO slumps after serious side effects mar Duchenne gene therapy results

REGENXBIO's shares declined 37% after a mixed data readout for its Duchenne muscular dystrophy gene therapy, RGX-202, from the Phase 3 portion of the AFFINITY...

Biogen pushing tau drug forward despite Alzheimer’s study failureClinical Trial Updates

15 May 2026

Biogen pushing tau drug forward despite Alzheimer’s study failure

Biogen announced "unprecedented and compelling" results from its Phase 2 "Celia" study of BIIB080 (diranersen) in early Alzheimer’s disease, despite the trial...

Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026Clinical Trial Updates

15 May 2026

Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026

Imviva Biotech announced encouraging clinical and translational data from its ongoing open-label Phase 1/2 study of CTA313, an investigational dual-targeted...

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesClinical Trial Updates

15 May 2026

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences announced its Q1 2026 financial results and provided key corporate updates. The company reported positive 12-month follow-on data from...

SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesClinical Trial Updates

15 May 2026

SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma reported its first-quarter 2026 financial results, showing a strong financial position with $251.0 million in cash, cash equivalents, and...

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesClinical Trial Updates

15 May 2026

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics announced a second philanthropic donation from Mr. Jeffrey Pechter, enabling the extension of its ongoing expanded access program (EAP)...

Forward Therapeutics Announces Completion of Phase 1 Trials with Two Internally Discovered Next-Generation TNF Signaling Inhibitors Supporting Advancement to Phase 2 Clinical DevelopmentClinical Trial Updates

15 May 2026

Forward Therapeutics Announces Completion of Phase 1 Trials with Two Internally Discovered Next-Generation TNF Signaling Inhibitors Supporting Advancement to Phase 2 Clinical Development

Forward Therapeutics, Inc. has successfully completed Phase 1 first-in-human trials for two internally-discovered oral small molecule TNF signaling inhibitors,...

Lilly Data Point to ‘Maintenance’ Strategies for GLP-1 Weight LossClinical Trial Updates

14 May 2026

Lilly Data Point to ‘Maintenance’ Strategies for GLP-1 Weight Loss

Eli Lilly has released new data demonstrating the effectiveness of its GLP-1 medicines in helping patients maintain weight loss long-term after initial...

AB Science reports its revenues for the year 2025 and provides an update on its activitiesClinical Trial Updates

14 May 2026

AB Science reports its revenues for the year 2025 and provides an update on its activities

AB Science reported its annual financial results for 2025, showing an operating loss of €3.8 million (excluding non-recurring items, down 38%) and a net loss...

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical BenchmarksClinical Trial Updates

14 May 2026

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Moleculin Biotech announced that its pivotal Phase 2B/3 MIRACLE trial, evaluating Annamycin in combination with cytarabine for relapsed or refractory acute...

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business HighlightsClinical Trial Updates

14 May 2026

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

Eledon Pharmaceuticals announced its first quarter 2026 financial results and significant business updates for its lead investigational product, tegoprubart....

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical ProgressClinical Trial Updates

13 May 2026

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

Zentalis Pharmaceuticals announced its Q1 2026 financial results and significant clinical advancements for its WEE1 inhibitor, azenosertib. The company...

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial ResultsClinical Trial Updates

13 May 2026

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Eupraxia Pharmaceuticals Inc. announced its financial results for the first quarter of 2026, reporting a net loss of $12.7 million, an increase from $6.8...

BridgeBio Stands Up to Pfizer in ATTR-CM with Late-Stage DataClinical Trial Updates

13 May 2026

BridgeBio Stands Up to Pfizer in ATTR-CM with Late-Stage Data

BridgeBio’s transthyretin amyloidosis drug Attruby elicited notable improvements in survival and hospitalization rates, pointing to its potential “superiority”...

Verrica Pharmaceuticals Reports First Quarter 2026 Financial ResultsClinical Trial Updates

13 May 2026

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

Verrica Pharmaceuticals announced its first-quarter 2026 financial results, showcasing significant growth for its commercial product, YCANTH (VP-102), for...

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 CongressClinical Trial Updates

13 May 2026

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology and Kyowa Kirin announced updated results from the Phase 1 KOMET-007 trial, evaluating ziftomenib in combination with cytarabine plus...

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateClinical Trial Updates

13 May 2026

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Atea Pharmaceuticals reported its first quarter 2026 financial results and provided a comprehensive business update, highlighting significant advancements in...

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateClinical Trial Updates

13 May 2026

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics reported its first quarter 2026 financial results and provided a business update, highlighting the ongoing Phase 1/2 study of its lead...

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association CongressClinical Trial Updates

13 May 2026

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

Nurix Therapeutics announced that updated efficacy and safety data from its ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with...

Inhibrx Delivers Differentiated Cancer Drug Data in Phase 2 TrialClinical Trial Updates

12 May 2026

Inhibrx Delivers Differentiated Cancer Drug Data in Phase 2 Trial

Inhibrx Biosciences announced positive mid-stage results for its experimental drug INBRX-106 in combination with Merck & Co.'s Keytruda for a type of head and...

Merck, Amgen double down on bad cholesterol to vanquish number 1 killerClinical Trial Updates

12 May 2026

Merck, Amgen double down on bad cholesterol to vanquish number 1 killer

New guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) are driving pharmaceutical companies to intensify efforts in...

Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology PortfolioClinical Trial Updates

12 May 2026

Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon announced new clinical data for its legacy oncology asset ANV600 (sunekafusp alpha) from the EXPAND-1 Phase 1 study, which will be presented at the...

Reunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ASCP and APA Annual MeetingsClinical Trial Updates

12 May 2026

Reunion Neuroscience to Present Full Data from RECONNECT Phase 2 Clinical Trial at Upcoming ASCP and APA Annual Meetings

Reunion Neuroscience announced it will present full results from its RECONNECT Phase 2 trial evaluating luvesilocin in adult female patients with...

Page 1 of 10Next →